Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

mAbs

Showing results (731-740 of 1,834) with videos related to

Pageof 184
Sort By:
Mabs|May 27, 2023
Generation and <i>in vivo</i> characterization of a novel high-affinity human antibody targeting carcinoembryonic antigenLouis Plüss, Frederik Peissert, Abdullah Elsayed, et al.
Mabs|May 27, 2026
High-throughput small-angle X-ray scattering reveals effective structure factor transitions linked to high-concentration antibody viscosityLateefat Kalejaye, I-En Wu, Jia-Min Chu, et al.
Mabs|May 27, 2026
Prediction of antibody non-specificity using protein language models and biophysical parametersLaila I Sakhnini, Ludovica Beltrame, Simone Fulle, et al.
Mabs|May 19, 2026
Novel bispecific T-cell engagers overcoming acquired EGFR resistanceLennart Kühl, Ann-Kathrin Löffler, Oliver Seifert, et al.
Mabs|June 8, 2026
Subcutaneous drug delivery of high concentration antibody products - part 2: formulation, device options, and clinical bridging strategies for patient-centric commercial presentationsIndrajit Ghosh, Suyash Deodhar, Hiten Gutka, et al.
Mabs|April 15, 2026
Preclinical characterization of AZD1163, a first-in-class anti-PAD2/4 bispecific antibody for the treatment of rheumatoid arthritisGary P Sims, Lacie Scaletta, John Andrews, et al.
Mabs|May 10, 2026
Discovery, development, and characterization of SPY002 and SPY072, two novel extended half-life monoclonal antibodies targeting TL1A: in vitro properties, in vivo pharmacology, pharmacokinetics, and preclinical safetyMatthew Siegel, Eric Zhu, Daniel Rios, et al.
Mabs|May 23, 2025
Process development for production of non-originator NISTmAb from CHO and NS0 cell linesErica J Fratz-Berilla, Nicole Azer, Xin Bush, et al.
Mabs|April 28, 2026
Engineering of acidic pH-responsive anti-CD3 binding antibodiesGrégory La Sala, Katharina B Kroell, Mudita Pincha, et al.
Mabs|April 28, 2026
Targeting IL-7Rα with PNU-159682 antibody-drug conjugates in acute lymphoblastic leukemia: translational implicationsShiqi Yang, Takahiro Anzai, Ryo Tsumura, et al.
Pageof 184

Showing results (731-740 of 1,834) with videos related to

Sort By:
Pageof 184
Mabs|May 27, 2023
Generation and <i>in vivo</i> characterization of a novel high-affinity human antibody targeting carcinoembryonic antigenLouis Plüss, Frederik Peissert, Abdullah Elsayed, et al.
Mabs|May 27, 2026
High-throughput small-angle X-ray scattering reveals effective structure factor transitions linked to high-concentration antibody viscosityLateefat Kalejaye, I-En Wu, Jia-Min Chu, et al.
Mabs|May 27, 2026
Prediction of antibody non-specificity using protein language models and biophysical parametersLaila I Sakhnini, Ludovica Beltrame, Simone Fulle, et al.
Mabs|May 19, 2026
Novel bispecific T-cell engagers overcoming acquired EGFR resistanceLennart Kühl, Ann-Kathrin Löffler, Oliver Seifert, et al.
Mabs|June 8, 2026
Subcutaneous drug delivery of high concentration antibody products - part 2: formulation, device options, and clinical bridging strategies for patient-centric commercial presentationsIndrajit Ghosh, Suyash Deodhar, Hiten Gutka, et al.
Mabs|April 15, 2026
Preclinical characterization of AZD1163, a first-in-class anti-PAD2/4 bispecific antibody for the treatment of rheumatoid arthritisGary P Sims, Lacie Scaletta, John Andrews, et al.
Mabs|May 10, 2026
Discovery, development, and characterization of SPY002 and SPY072, two novel extended half-life monoclonal antibodies targeting TL1A: in vitro properties, in vivo pharmacology, pharmacokinetics, and preclinical safetyMatthew Siegel, Eric Zhu, Daniel Rios, et al.
Mabs|May 23, 2025
Process development for production of non-originator NISTmAb from CHO and NS0 cell linesErica J Fratz-Berilla, Nicole Azer, Xin Bush, et al.
Mabs|April 28, 2026
Engineering of acidic pH-responsive anti-CD3 binding antibodiesGrégory La Sala, Katharina B Kroell, Mudita Pincha, et al.
Mabs|April 28, 2026
Targeting IL-7Rα with PNU-159682 antibody-drug conjugates in acute lymphoblastic leukemia: translational implicationsShiqi Yang, Takahiro Anzai, Ryo Tsumura, et al.
Pageof 184